UK's CAT outlines ambitious growth plans

Cambridge Antibody Technology is unveiling some ambitious growth plans. CAT, which was recently acquired by AstraZeneca, has leased a 92,000-square-foot lab and office complex and plans to start hiring new staffers in the UK. The new building will house up to 300 employees. AstraZeneca is looking to CAT's work in antibodies to provide some of the exciting new drug discoveries its own lab has failed to produce.

- here's the report on CAT's plans from Siliconfen Business

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.